In conclusion, available data suggests considerable potential for HDAC6 inhibition to improve outcomes following AIS, evidenced by reductions in the severity of brain infarction and improvements in neurological function, even when treatment is delayed by up to 24 h. The gene discussed is HDAC6; the disease is brain infarction.